Ferdinandos Skoulidis
MD, PhD
Associate Professor of Thoracic Medical Oncology
👥Biography 个人简介
Ferdinandos Skoulidis has defined the impact of co occurring mutations such as STK11 and KEAP1 on response to KRAS G12C inhibitors and immunotherapy in lung cancer. His work supports rational combinations with SHP2 inhibitors and immune checkpoint blockade. He co led CodeBreaK trials of sotorasib combinations.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Ferdinandos Skoulidis 的研究动态
Follow Ferdinandos Skoulidis's research updates
留下邮箱，当我们发布与 Ferdinandos Skoulidis（MD Anderson Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment